Prophylaxis News and Research

RSS

Vesicoureteral reflux more common among girls

Children with vesicoureteral reflux (VUR), in which urine flows backwards into the kidneys from the bladder, have been treated in the past with surgery or antibiotic therapy.

21 May 2010

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

As US policymakers consider scaling back on its historic initiative to fight AIDS around the world and downsizing goals to combat tuberculosis, next-generation treatment and prevention strategies to significantly reduce the spread of HIV/AIDS and tuberculosis are now imminent. New science can dramatically change the trajectory of both deadly epidemics, according to a special new issue of the journal Clinical Infectious Diseases.

21 May 2010

AP examines HIV microbicides, prep research

"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.

19 May 2010

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

For more than a decade, researchers and advocates have marked HIV Vaccine Awareness Day with varying degrees of hope, cynicism and despair. This year, in large part because of the results of the Thai Prime-Boost vaccine study, there is greater cause for hope than ever before and a renewed sense of urgency to transform this hope into a reality.

18 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Hepatocellular carcinoma is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulative function. Surgical resection is the best option to cure HCC, however, surgery on cirrhotic liver may increase the risk of bleeding.

12 May 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale.

7 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, "A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants."

5 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

FDA issues complete response letter for Bristol-Myers Squibb's belatacept

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the Biologics License Application for belatacept in kidney transplantation.

3 May 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

DENTSPLY International reports 7.7% increase in first-quarter 2010 net sales

DENTSPLY International Inc. today announced sales and earnings for the three months ended March 31, 2010. Net sales in the first quarter of 2010 increased 7.7% to $545.9 million compared to $506.9 million reported for the first quarter of 2009.

29 Apr 2010

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.

29 Apr 2010

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application for sirolimus tablets in the 1 mg and 2 mg strengths.

29 Apr 2010

Prophylaxis News and Research

Vesicoureteral reflux more common among girls

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

AP examines HIV microbicides, prep research

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

Final data from Open-Label studies of Cinryze in patients with HAE now available

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Risk of venous thromboembolism is low after hepatic resection in cirrhotic patients: Researchers

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

Implementation of quality improvement intervention reduces medication use in premature babies: Study

FDA issues complete response letter for Bristol-Myers Squibb's belatacept

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

DENTSPLY International reports 7.7% increase in first-quarter 2010 net sales

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News